Synlogic Inc. (SYBX)
1.39
0.08 (6.11%)
At close: Mar 07, 2025, 3:58 PM
1.31
-5.81%
Pre-market: Mar 06, 2025, 10:55 AM EST
6.11% (1D)
| Bid | 1.29 |
| Market Cap | 16.26M |
| Revenue (ttm) | 2.66M |
| Net Income (ttm) | -42.29M |
| EPS (ttm) | -1.5 |
| PE Ratio (ttm) | -0.93 |
| Forward PE | -3 |
| Analyst | n/a |
| Ask | 1.36 |
| Volume | 3,705 |
| Avg. Volume (20D) | 39,633 |
| Open | 1.39 |
| Previous Close | 1.31 |
| Day's Range | 1.39 - 1.39 |
| 52-Week Range | 1.22 - 2.04 |
| Beta | 0.72 |
About SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase II clinical trials to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 30, 2015
Employees 6
Stock Exchange NASDAQ
Ticker Symbol SYBX
Website https://www.synlogictx.com
